AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ENDEAVOR BIOMEDICINES · Biotechnology & therapeutics

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $51,000.00 income · posted Jul 17, 2026

Bills named in this filing 1

Lobbying activity 1

Health Issues

FAIR Act HR 7953 FDA Modernization

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.